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Abstract
In evidence-based weight-loss programs weight regain is common after an initial weight
reduction. Eating slowly significantly lowers meal energy intake and hunger ratings. Despite
this knowledge, obese individuals do not implement this behaviour. We, thus tested the
hypothesis of changing eating behaviour with an intra-oral medical device leading to con-
stant weight reduction in overweight and obesity.
Six obese patients (6 men, age 56 ± 14, BMI 29 ± 2 kg / m2) with increased CVRF profile
were included in this prospective study. All patients had been treated for obesity during the
last 10 years in a single centre and had at least 3 frustrate evidence-based diets. Patients
received a novel non-invasive intra-oral medical device to slow eating time. Further advice
included not to count calories, to avoid any other form of diet, to take their time with their
meals, and to eat whatever they liked.
This device was used only during meals for the first 4 to 8 weeks for a total of 88 [20–160]
hours. Follow-up period was 23 [15–38] months. During this period, patients lost 11% [5–
20%] (p<0.001) of their initial weight. At 12 months, all patients had lost >5%, and 67% (4/6)
achieved a >10% bodyweight loss. In the course of the study, altered eating patterns were
observed. There were no complications with the medical device. Of note, all patients contin-
ued to lose weight after the initial intervention period (p<0.001) and none of them had weight
regain.
With this medical device, overweight and obese patients with a history of previously frus-
trating attempts to lose weight achieved a significant and sustained weight loss over two
years. These results warrant the ongoing prospective randomised controlled trial to prove
concept and mechanism of action.
Trial registration: German Clinical Trials Register DRKS00011357
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Introduction
Substantial and sustained increase of total energy intake worldwide has led to increased body
weight across the global population, with an estimated 1.5 billion overweight individuals [1].
Obesity is a significant public health problem [2] [3], resulting in a heightened risk of diabetes,
cardiovascular disease, cancer and other illnesses [4] [5] [6] [7]. The abundance and perma-
nent availability of high-caloric food and the habitual sedentary lifestyle on the background of
evolutionary engraved and perinatally imprinted physiological response patterns are key fac-
tors for individual and global weight gain.
Consequently, rectifying this imbalance by caloric restriction and increased physical activity
form the basis in the management of evidence-based interventions of obesity [8] [9]. However,
although programs including dietary restrictions, physical activity and behaviour modification
can and do lead to weight loss [10], over the long term, the majority of individuals regain the
weight they have lost [11]. Weight stability after weight reduction programs requires profound
and permanent changes in lifestyle and eating behaviour [12]. Not only is weight regain frus-
trating for the individual, weight fluctuation is also an independent predictor for disease bur-
den [13]. Despite the prevalence of evidence-based diets and programs, losing weight and
preventing weight regain in overweight and obesity remains a serious challenge. It is apparent
that the effects of diet and exercise interventions alone are not sufficient to support long-term
maintenance of a reduced weight [14].
Obesity can be regarded as a neurobiological disease with a psychological element. The
mechanisms underlying flawed eating behaviour are complex. Several physiologic adaptations
after voluntary weight loss favour weight regain. These involve appetite-related hormones
[15], the complex neuro-hormonal system, hedonic and reward circuits, and changes in energy
expenditure. [12] [16]. The restraint theory provides an attempt to synthesise the behavioural,
cognitive and affective components of the food intake process [17]. Unusual eating patterns
are proposed to develop as a result of the stress associated with the demands of continual self-
control [18], with food intake determined by a balance between the desire to eat and the aspi-
ration to diet. [19]. That is, cognitive processes override physiological hunger and satiety cues
[20]. Over the long-term, the more powerful emotions may override cognitive control and
result in over-eating, which is often seen in individuals after consequent dieting.
With the acceleration of obesity rates and few effective obesity treatment options, new strat-
egies addressing changes of eating behaviour are urgently needed. Successfully maintaining
weight loss requires a permanent change of behaviour.
We thus tested that hypothesis that a relatively short period of using an intraoral device to
change eating behaviour in overweight and obesity could lead to a constant and long-lasting
weight reduction.
Materials and methods
This was a prospective investigator-initiated, open-label therapy trial to test an innovative oral
medical device designed to reduce chewing area (patent application DE102012015839A1,
EP000002695588A1, US-Application no. 13/961,024). The study was conducted in a single
centre in a specialist practice from July 2012 to January 2015. Recruitment of patients was
from July 2012 to August 2014 Patients with clinical indication for weight reduction were pro-
spectively recruited to test the intraoral device. Sponsor of this study were the physician and
patent holder and the collaborating orthodontist. The physician conducted the study together
with assisting personnel. He took no part in analysis or preparation of the manuscript. All
study participants gave written informed consent. This study in accordance with the Helsinki
convention and was approved by the locals Ethics Committee (FF 1/2015) Landesa¨rztekammer
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Hessen (Frankfurt, Germany). The study has been registered in the German Clinical Trials
Register on 8.12.2016 and has been assigned the number DRKS00011357. The study was initi-
ated and carried out by a senior general practitioner and his befriended patients to prove the
concept. They were not aware of the requirement to register.
Participant selection
Participants were recruited in the practice if they fulfilled the following eligibility criteria: BMI
25.0–29.9 kg/m2 with other risk factors (i.e. hypertension, diabetes, abdominal obesity) or BMI
over 30.0 kg/m2; at least 2 previous evidence-based weight management programmes with
consecutive weight regain in the last years ( 1kg / year); will to reduce weight; age 18–75
years; increased cardiovascular risk profile to develop cardiovascular disease by considering
age>65 years, male sex, hypertension, diabetes, and smoking for coronary artery disease as
single cardiovascular risk factors (more than 3 individual factors [21]); dental examination
within the past 12 months; good oral health and functioning occlusion. Exclusion criteria were
participation in a weight reduction programme during the last 6 months prior to this study,
weight fluctuation of 5% over the last year, uncontrolled eating behaviour, clinical or bio-
chemical evidence for the presence of concomitant chronic inflammatory disease, presence of
any other significant uncontrolled medical condition or any other treatment known to alter
appetite or weight, obesity due to secondary disorders, inability to understand the consent
form, participation in or consent to participate in another study, malignant disease, wearing
dental prosthesis, less than 10 teeth /jaw with maximally mild to moderate periodontal disease,
and poor oral/dental health (as confirmed by the trial dentist).
Study protocol
Patients who fulfilled the above-mentioned inclusion and exclusion criteria were sent to the
orthodontist (consultant to the project) for baseline testing and preparation of dental impres-
sions using a purpose-designed kit (Fig 1). The device was custom-made for each individual
from the individual’s dental impressions. When needed, the orthodontist adjusted the tool to
ensure that it fit securely prior to commencement of use. Patients were advised to refrain from
using the device if they felt any problems and to consult the orthodontic at their earliest conve-
nience. On the day of device dispensation (day 1), each participant attended the practitioner
for a consultation and baseline measurements. Participants were encouraged to use the device
for all meals. Further advices included to strictly avoid sweetened or sugary drinks, avoid any
cognitive control over their eating behaviour and to eat what they felt was best for them: in
other words, to refrain from any conventional caloric-restricted diet or meal supplements, to
eat when and what they liked, to take their times with their meals, savouring every bite and eat-
ing mindfully [22], and to take up physical activity only if they felt like it. Patients were advised
to use the device for all meals for the first 8 to 12 weeks (Phase I). They were told not to use the
device thereafter (Phase II), but allowed to place the box with the device next to them when
eating for remembrance.
Participants attended follow-up appointments in the practice at weeks 2, 4, 6, 12, and at
months 6, 9, 12, 15, 18, 24, 30 and 36. Weight, compliance, adverse events (AEs), and qualita-
tive feedback were obtained during each consultation. For AEs, a standardised questioning at
each contact was performed.
The intraoral device
The novel intraoral device has been designed to slow the eating process, with the intent of pro-
longing the chewing process and delaying the swallowing of a single bite in order to improve
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the function of physiological satiation mechanisms. Additionally, the duration of the single
bite in the mouth should be extended to intensify the tasting of the food. Thereby the device
aims to promote mindful eating and a long-lasting change in eating behaviour.
The design of the intraoral device consists of two thermoplastic splints made of Polyethy-
lenterephthalat-Glycol (PET-G) for the upper and lower jaw (Fig 2). On top of each splint a
smooth layer made of Polymethylmetacrylate (PMMA) is formed, which reduces the occlusal
surface in centric jaw occlusion. Additionally, a linear increase with a width of about 3mm
over the upper premolars and molars further reduces the chewing area. Thus, the occlusal sur-
face is reduced to about one fourth of its original surface. The completely smooth surface of
the splint that covers the lower jaw further restricts the chewing process by inhibiting the inter-
locking of dental cusps. The device is inserted immediately before ingestion of food and is
removed afterwards.
Clinical assessment and questionnaires
Weight was measured at baseline and each follow-up (see above), using the same digital scales.
Patients’ historical weight was retrieved from the individual records. At baseline and last fol-
low-up, height, weight and waist circumference were quantified and the body mass index
(BMI, kg / m2) calculated. Supine blood pressure was measured in the left arm. Venous blood
samples were taken at baseline and after 3 and 6 months, as clinically indicated, to assess
Fig 1. Flowchart.
https://doi.org/10.1371/journal.pone.0174528.g001
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plasma glucose, insulin, haemoglobin A1c (HbA1c), total, high-density lipoprotein and low-
density lipoprotein cholesterol and triglycerides. These samples were taken after an overnight
fast. Concomitant medication was assessed at baseline and changes monitored throughout the
study.
To exclude participants with uncontrolled eating behaviour, volunteers were screened for
uncontrolled eating behaviour using the German version of the Three Factor Eating Question-
naire (TFEQ) [23]. A questionnaire, specifically designed for this study, assessed participants’
acceptability of the intraoral device, eating rates, food choices, comfort, appetite, and meal size
throughout Phase I. Responses were noted by the practitioner and evaluated at the completion
of the study.
Fig 2. Medical device on dental model. (A) Splints are almost invisible on the front teeth of the upper and
lower jaws. (B) linear increase over the upper posterior molars reduces the chewing area to about one fifth.
https://doi.org/10.1371/journal.pone.0174528.g002
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Compliance
Compliance throughout Phase I of the study period was defined as reported by participants.
Good compliance as use of a minimum use of 3 meals/day, 6 days/week; moderate compliance
as use of 15 to 18 meals/week; poor compliance as use of 9 to 14 meals/week; less than 9 meals/
week was defined as no compliance. These values were averaged to obtain a “mean uses per
week” across the Phase I of the study for each participant. Additionally, length of use in weeks
and cumulative duration of use in hours were recorded.
Adverse events and qualitative data
At each visit, participants were asked to report any adverse events; these were recorded, and
where necessary, follow-up action was taken by the medical officer or dentist.
Assessment of eating with the device
In their first week, the last three participants included in the observation volunteered to
participate in an additional acute eating experiment with the device. For this, they were
asked to eat an identical ad-libidum meal (lunch) on two following days at home without
the device (baseline) and on the following day with the device. All volunteers were in-
structed to eat a light breakfast on the test days. They all reported to have followed the
instructions.
Appetites were measured with a German translation of the Visual Analog Scale (VAS)
[24] and additional standardised questions assessing chews per bite, duration (in seconds)
to swallow, percentage of consumed meal, satisfaction from the meal, awareness of food
composition and amount of food consumed, duration of the meal, intake of a snack after
2–3 hours and type of snack following each meal. Changes of eating behaviour and appetite
following the meals were assessed by comparison of the individual questionnaires from day
2 with baseline. Food intake motivation after the respective test meals was assessed with the
use of a paper version of the VAS, completed directly afterwards on a 100-mm line. The
scales assessed: hunger (How hungry do you feel at this moment?), desire to eat (How
strong is your desire to eat at this moment?), fullness (How full does your stomach feel at
this moment?), and motivation to eat (How much food do you think you could eat at this
moment?). These VAS ratings have been determined to be valid and reliable indicators of
hunger and satiety VAS. [24]
Statistical analysis
Data are expressed as mean ± standard deviation (SD). All continuous variables were assumed
not to be normally distributed due to the small number of patients included and compared
with the Mann-Whitney U test. Comparison of categorical variables was generated by the
Pearson χ2 test and the Fisher’s exact test. Primary outcomes (weight loss in Phase I and Phase
II) were assessed on an intention-to-treat basis. A total of 6 patients will enter this study. The
probability is 80 percent that the study will detect a relationship between the independent and
the dependent variables at a one-sided 0.05 significance level, if the true change in the depen-
dent variables is 2.484 units per one standard deviation change in the independent variable in
a test to find an association if the dependent variable is affected by the treatment. This is based
on the assumption that the standard deviation of the dependent variable is 2.
Statistical significance was assumed if a null hypothesis could be rejected at p0.05. All sta-
tistical analysis was performed with SPSS 21.0.
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Results
Patient characteristics
From among the practice, 12 patients were identified as meeting eligibility criteria and offered
to test the novel medical device. Of these, 9 consented to participate. Of these, 1 patient had
dental exclusion, 1 lost his device on a longer trip abroad (week 2) and 1 patient felt uncom-
fortable with the device (week 1). Six patients participated in and completed the study and
were used for analysis (Fig 1). None of the patients had a depression or eating pathology on
food intake and appetite. The demographic, anthropometric, clinical, and biochemical charac-
teristics of the 6 patients at baseline and at last follow-up are summarised in Table 1. As shown
in Fig 3A, patients had a documented average increase of their bodyweight over the last 4 to 12
(8 ± 2.6) years of 10.4 ± 8.3 kg, p<0.05) prior to receiving the device, despite undertaking at
least 2 lifestyle modifying programs to lose weight. Follow-up of the study was 15 to 38
(23.2 ± 10.0) months.
Weight loss and compliance
All patients significantly lost weight during the initial Phase I (6.8 ± 3.3 kg or 7.3 ± 3.6% of
baseline bodyweight after 3 months, p < 0.05, Fig 3B and 3C) where they wore the device.
Interestingly, all patients continued to lose weight in Phase II (4.0 ± 4.1 kg during Phase II,
p< 0.05) without usage of the device, achieving our primary weight-loss objective of a long-
term change of eating behaviour (10.5 ± 4.2 kg or 11.0 ± 4.9% of baseline bodyweight for last
follow-up, p< 0.01, Fig 3B and 3C). All patients lost >5% initial bodyweight, and 67% (4/6)
achieved a>10% bodyweight loss over the whole study period. When restricting the observa-
tion period to 12 months similar success rates were measured, since all patients had lost >5%,
and 67% (4/6) achieved a>10% bodyweight loss. Waist circumferences also decreased signifi-
cantly (−9.4 ± 3.6 cm, p< 0.05).
After receiving the device, patients used the device between 4 to 10 (7 ± 2) weeks. The wide
range is explained by a self-reported significant weight loss due to a change in eating behaviour
in 2 patients, who were than allowed to eat without the device. Four patients were defined as
Table 1. Baseline characteristics and demographic variables.
Parameter Pre-Study 1 Baseline Last Follow-up Change Significance
Age 56 ± 14
Male gender 100%
Bodyweight (kg) 83 ± 6 93 ± 7 83 ± 4 2 10.4 ± 8.3 kg 0.01
3 - 10.5 ± 4.2%
BMI (kg/m2) 26 ± 1 29 ± 2 26 ± 2 0.01
Waist circumference (cm) n. d. 108 ± 3 98 ± 4 3 - 10 ± 4 0.05
SBP (mmHg) 137 ± 8
DBP (mmHg) 82 ± 4
HbA1c (%) 6.1 ± 0.8 5.8 ± 0.6 n.a.
n = 2
Physical activity (h / week) 1.6 ± 0.9 1.7 ± 1.0
Cumulative number of CVRF 3.8 ± 0.8
Table legend: CVRF, cardiovascular risk factors; DBP, diastolic blood pressure; SBP, systolic blood pressure
1 historical data from patients records (period ranged from 4 to 12 (8 ± 2.5) years
2 difference pre-study to baseline.
3 difference baseline to last follow-up.
https://doi.org/10.1371/journal.pone.0174528.t001
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Fig 3. Changes of body weight of participants during the trial. (A) Change of body weight of all
participants prior (4 to 12 years) to testing the device and at inclusion (baseline). (B) Individual change of body
weight for all participants during the trial prior to the study (pre-study), -> indicated first usage of the medical
Innovative medical device for weight reduction
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fully compliant, 1 as moderately and 1 as poor compliant according to the practitioners assist-
ing personnel (2 independent judgements). Cumulative use of the device for the individual
patient was 20 to 160 (100 ± 57) hours.
Safety and acceptability
There were no adverse events with the device reported. All patients reported uncomfortable
foreign body sensation with the device that subsided after 1 week (n = 2), 2 weeks (n = 3), or
after 4 weeks (n = 1). Further discomfort was reported by 2 patients, related to mild gingivitis
that required re-adjustment by the orthodontist (n = 1), intermediate difficulties with biting
and chewing some food (salads and certain meat) and attracting another person’s attention
(n = 1) during eating and were reported to be “rare” or “very rare”. Apart from these events
related to the device, no other incidences occurred. In general, patients reported that handling
of the device for insertion and removal was “very good” or “good” in 4 cases and to be “accept-
able” in 2 cases. Three patients would recommend the device “unreservedly” and 3 “more yes”
(on a scale to five).
Change in eating behaviour
As shown in Table 2, all patients noticed a change of eating behaviour. Three patients reported
using the device as a reminder on rare occasions, whereas the others refrained from using the
device as reminder.
Changes in food intake were considerable and similar in all three volunteers between eating
without (baseline) or with the device, as shown in Table 3. Using the device, there was an
increase in chews per bite (3-fold), time to swallow a bite (3.5-fold), and duration of the meal
device, Phase I is the time period where patients used the device (4 to 10 weeks), Phase II is the follow-up
period, during which the device was no longer used. (C) Average change of body weight for all participants
during the trial. Boxplots’ bar are medians, grey area represent 25 to 75 IQR, and whiskers are 5th to 95th
percentiles. * indicates p <0.05, ** indicates p < 0.005.
https://doi.org/10.1371/journal.pone.0174528.g003
Table 2. Changes of subjective eating behaviour and quality of life during long-term follow-up.
Description Value (on a scale of five ordinal values,
1 = best, 5 = worst, unless otherwise
indicated)
1 2 3 4 5
Reduction of dose and amount of concomitant medication 2 1 3 0 0
Eating with pleasure (1 = more pleasure) 1 3 2 0 0
Prolonged time to eat meals 4 2 0 0 0
Choice of food more “natural” 2 3 1 0 0
Frequency of snacks in between meals (1 = less) 3 2 1 0 0
Counting calories (1 = never) 3 1 2 0 0
Noticed change of behaviour 4 2 0 0 0
Hunger / appetite between meals 4 2 0 0 0
Refreshing sleep 4 0 1 0 0
Increased gut feeling / less cognitive control 4 2 0 0 0
Less tired after meals 6 0 0 0 0
Improved overall health 3 3 0 0 0
Comparison after last follow-up with baseline, Numbers indicate sum of patients’ choice
https://doi.org/10.1371/journal.pone.0174528.t002
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to satiety (3.5-fold), whereas the size of the meal consumed was reduced to 59%. Awareness of
composition and amount of food consumed was higher with the device in the acute test meal
setting and patients reported during a long-term follow-up that this effect continued.
Discussion
The findings of this study support the hypothesis that this medical device is the first non-inva-
sive medical device to reduce weight in overweight and obesity effectively and enduringly. Our
data indicate that this weight loss is a result of a sustainable change in eating behaviour.
What’s more, the approach of this therapy strongly contrasts with contemporary weight loss
strategies in that all patients were instructed to eat whatever they liked.
Treatment of obesity includes food consumption because this is the primary source of calo-
ric intake and manipulating eating behaviour thus is a primary target. Commonly, weight loss
strategies to fight individual and populations overweight and obesity include behaviour modi-
fication, pharmacotherapy, meal replacements, and more drastically, gastric bypass surgery, or
gastric balloon. Despite proven short- and medium-term weight reduction of these evidence-
based programs, rapid weight gain is a serious health problem [13] for the majority of patients
trying to lose weight.
All patients with increased cardiovascular risk profile who were included in our study had
increases in weight despite previous evidence-based strategies to reduce weight over the last
years. Participants all lost weight in the first phase, when they used the device for their meals
and reported to have changed both the size of their meals as well as the choice of food con-
sumed during this first acute phase of only a few weeks. To verify this finding, an acute experi-
ment was conducted in a subgroup of patients, where patients showed prolonged eating
duration, increased awareness of food composition and feelings of satiety, although they had
eaten smaller meals when eating with the device. Satisfaction and compliance with the medical
device in our study was acceptable after initial discomfort and no adverse events occurred.
Thus, this device is different from other medical intra-oral devices that attempt to prevent
an individual from eating but do not change eating behaviour.
There is a strict relationship between bite size and food intake [25] as well as oral health sta-
tus and involuntary weight loss [26]. First experiences have been made with intraoral medical
devices to restrict food consumption in obesity. An oral volume restriction device modified
the subjects’ bite size, but this was not associated with changes in food consumption, hunger
or satiety feelings [27] [25]. Overweight patients lost weight during a short follow-up period of
Table 3. Changes of eating and hunger at baseline without (w/o) or with (w) the medical device eating a standardised meal.
Description Patient Average Baseline Average Device Change (in %)
1 2 3
w/o w w/o w w/o w
Chews / bite 9 25 10 20 7 25 9 ± 1 27 ± 7 300
Time to swallowing (in seconds) 7 20 5 10 5 18 6 ± 2 22 ± 17 366
Percentage of consumed meal (in %) 100 50 100 66 100 50 100 ± 0 59 ± 9 - 41
Duration of the meal (in minutes) 12 25 30 45 10 25 17 ± 11 36 ± 10 212
Awareness of food composition (1 = full, 5 = poor) 3 1.5 1.5 1.5 2 2 2 ± 1 1.8 ± 1
Awareness of amount of food (1 = full, 5 = poor) 5 2 2 2 4.5 1.5 3.8 ± 1 2 ± 1
Pleasure from food (1 = full, 5 = poor) 1.5 1.5 3 3 1.5 1.5 2 ± 1 2 ± 1
Feeling hungry immediately after the meal (1 = no, 5 = very much) 0 0 0 0 0 0 0 ± 0 0 ± 0
Feeling hungry 2 to 3 hours after the meal (0 = no, 5 = very much) 1 0 1 0 0 0 0.7 ± 0.6 0 ± 0
https://doi.org/10.1371/journal.pone.0174528.t003
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4 months with an oral restriction device [28], however data from long-term follow-ups are not
available. Two other approaches to prevent obese patients from overeating were wiring of jaws
and intermaxillary fixation. [29] [30]. Both procedures achieved significant initial weight loss,
but when the devices were removed weight was regained [31]. Another group studied a tongue
patch for impeding swallowing combined with a low-calorie diet. Within the very small num-
ber of patients available for follow-up, 84% of patients maintained their initial weight loss dur-
ing 3 months to 4 years [32] with high drop-out rates.
The change of eating behaviour translated into sustained weight loss in the consecutive
months in the second phase during long-term follow-up, where the patients continuously lost
weight without using the device. During long-term follow-up, all of the patients in our study
significantly lost weight in a range defined as effective program [33].
Complex neurophysiological changes during cognitive control and unusual eating patterns
of individuals have been identified as strong inducers of weight regain. Our approach to help
overweight and obese patients to lose weight thus used this knowledge to change their behav-
iour and allow them to eat what they pleased. Our patients were not simply forced to eat
slowly, but given the opportunity to savour [33] and indulge each and every bite. Thus, the two
competing goals—namely, the aspiration to diet induced by cognitively inhibiting chronic
self-control and the desire to eat with pleasure seem reconcilable by the use of this simple med-
ical device.
This study has several limitations, such as the small number of 6 patients, the retrospective
design of long-term follow-up with limited phenotypic data at inclusion and the long recruit-
ment period as well as the lack of a control arm. We cannot exclude the possibility that patients
have been included in this study who previously failed to reduce weight because of cravings
caused by the sensory deprivation of monotonous diets.
Thus, a more powerful study is now conducted with a large number of patients in a pro-
spective, randomised, controlled multicentre trial. This is to prove the concept and the under-
lying mechanism. Since the majority of patients will regain weight after conventional dieting,
our approach may prove a serious alternative treatment for obesity in obese and overweight
patients for whom evidence-based options have failed.
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